The Sleep in Pregnancy Study

Overview

Sleep disordered breathing (SDB) insidiously worsens metabolic function, heightens insulin resistance (IR), and in pregnancy is thought to precipitate gestational diabetes, preterm birth, growth restriction, gestational hypertension, and preeclampsia. Despite the fact that sleep disturbances are common during pregnancy, SDB remains under-recognized, under-diagnosed, and poorly understood, particularly in pregnancies affected by obesity. Sixty percent of pregnancies are now affected by obesity, yet the relationship between SDB, patterns of glycemia, and insulin resistance (IR) in obese pregnant women is a neglected area with major therapeutic implications to improve maternal and infant health. Using a prospective design in which diet and gestational age are highly controlled, the investigators propose to measure SDB (apneas/hypopneas) in obese pregnant women using an ambulatory sleep monitoring system. In parallel, robust patterns of glycemia will be measured with a continuous glucose monitoring system (CGMS), followed by a 75g oral glucose tolerance test to measure insulin action. The investigators global hypothesis is that worse SDB in part accounts for higher 24-hour patterns of glycemia in obese normal glucose tolerant (NGT) pregnant women in their 3rd trimester. The Investigators will test the hypothesis that: 1) In obese NGT pregnant women at 32-34 weeks gestation on a controlled eucaloric diet, higher apnea hypopnea index (AHI) will be positively associated with 24-hour glycemia measured by a CGMS and that, 2) Higher AHI in obese NGT pregnant women at 32-34 weeks gestation on a eucaloric controlled diet will be associated with higher insulin resistance measured by a 75g oral glucose tolerance test (Matsuda Model). Early identification and treatment has the potential to decrease long-term maternal cardiovascular morbidity and mortality.

Full Title of Study: “Sleep Disordered Breathing Accounts for Abnormal Glycemic Profiles in Pregnant Women: The Sleep in Pregnancy (SiP) Study”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: March 15, 2018

Clinical Trial Outcome Measures

Primary Measures

  • 24 hour glycemia measurement of the Pregnant Mother
    • Time Frame: Every 24 hours for 3 days
    • Glycemia will be measured by Continuous glucose monitoring
  • Evaluation of Insulin resistance of the Pregnant Mother
    • Time Frame: 2 hours after a 75 gram glucose load
    • Insulin resistance will be measured with an Oral Glucose Tolerance Test

Secondary Measures

  • Infant Body Composition
    • Time Frame: At 2 weeks of life
    • Percent of Fat Mass
  • Stress Levels
    • Time Frame: 15 minutes before Sleep and 15 minutes after sleep
    • Cortisol Levels

Participating in This Clinical Trial

Inclusion Criteria

  • Pregnant women: 1. Between the ages of 20-39 yrs, 2. At 32-34 weeks gestation, 3. Who have a BMI of ≥30 to ≤40 kg/m2, 4. Who have a singleton pregnancy, and 5. Who have a normal glucose tolerance test on entrance to the study. Exclusion Criteria:

  • Pregnant Women: 1. Who have a diagnosis of diabetes (GDM, type 1 or type 2), 2. Who are using beta blockers/glucocorticoids. 3. Who have other children who are ≤2 yrs old (due to risk of disrupted sleep), 4. With diagnosed sleep disorders (e.g. OSA, insomnia, restless leg syndrome), 5. Who work night or rotating shifts, 6. Who report use of sleep medications will be excluded, 7. With diagnosed pulmonary or cardiovascular disease 8. Who do not speak English.

Gender Eligibility: Female

Minimum Age: 20 Years

Maximum Age: 39 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • University of Colorado, Denver
  • Collaborator
    • Center for Womens Health Research at University of Colorado Anschutz Medical Campus
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Sarah S Farabi, PhD, Principal Investigator, University of Colorado – Anschutz Medical Campus

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.